Skip to main content
editor@ajptr.com
9409046853
e-ISSN: 2249-3387
American Journal of PharmTech Research

American Journal of PharmTech Research

Published

ARTIFICIAL INTELLIGANCE DRIVEN TRANSFORMATION IN REGULATORY AFFAIRS AS PER CDSCO in (India) IN COMPARISION WITH HEALTH CANADA (Canada)

Published in October 2026 Issue 5 (Vol. 16, Issue 5, 2026)

ARTIFICIAL INTELLIGANCE DRIVEN TRANSFORMATION IN REGULATORY AFFAIRS AS PER CDSCO in (India) IN COMPARISION WITH HEALTH CANADA (Canada) - Issue cover

Abstract

ABSTRACT: Artificial Intelligence (AI) is emerging as a transformative technology in pharmaceutical regulatory affairs, enhancing efficiency, accuracy, and regulatory decision-making throughout the product lifecycle. Recent studies have demonstrated the application of AI and Machine Learning (ML) in regulatory intelligence, dossier preparation, document management, pharmacovigilance, signal detection, and compliance monitoring. Regulatory agencies worldwide are increasingly exploring AI-driven approaches to streamline regulatory submissions and improve review processes while maintaining safety, efficacy, and quality standards. This review aims to evaluate the role of AI in transforming regulatory affairs and to compare the adoption and implementation of AI-enabled regulatory practices by the Central Drugs Standard Control Organization (CDSCO), India, and Health Canada. The study examines current applications of AI in regulatory operations, including automated document review, adverse event monitoring, data analytics, and decision-support systems. Furthermore, it assesses the opportunities, challenges, and regulatory considerations associated with AI integration, such as data governance, transparency, validation, ethical concerns, and workforce readiness. The study concludes that AI has the potential to reshape the future of regulatory science by improving operational efficiency and regulatory effectiveness. Strategic adoption of AI technologies by regulatory authorities can contribute to faster access to safe and effective medicines while maintaining high regulatory standards4.

References

  1. [1]AI is a broad field of computer science focused on creating systems that can perform tasks that normally require human intelligence and Examples: Speech recognition (e.g., Siri), image recognition, decision-making, language translation, autonomous vehicles. Drug discovery & non-clinical development- Target identification, in-silico ADMET prediction, candidate selection. Regulatory questions: validation of in-silico models, reproducibility, transparency of inputs. Clinical development and trial design- AI for patient selection, synthetic control arms, adaptive trial designs, predictive biomarkers, and decentralized trials. Automatically screen and validate regulatory submissions. Detect incomplete application data. Overall, Health Canada’s approach highlights the importance of responsible AI adoption, providing valuable guidance for strengthening regulatory efficiency, transparency, and public trust13. Lastly, we are grateful to all those people who have been instrumental in the completion of this article. Central Drugs Standard Control Organisation (CDSCO). Overview of CDSCO's regulatory framework [Internet]. Available from: https://cdsco.gov.in [cited 2026 Sep 17]. Health Canada. Overview of Health Canada regulatory framework [Internet]. [cited 2026 Aug 19]. Available from: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/precision-regulating-authorities-under-food-drugs-act.html AI clinical applications in Health Canada (CADTH) [Internet]. [cited 2026 Aug 22]. Available from: https://www.cda-amc.ca/overview-clinical-applications-artificial-intelligence Health Canada presentation on regulatory challenges of AI products [Internet]. 2023 Sep 27. Available from: https://www.cadth.ca/sites/default/files/symp-2019/presentations/april15-2019/A3-presentation-tdumouchel.pdf Canadian Foundation for Healthcare Improvement. Artificial intelligence (AI) in healthcare [Internet]. [cited 2026 Aug 22]. Available from: https://www.cfhi-fcass.ca/opportunities/webinars/artificial-intelligence-in-healthcare 7 ways AI is impacting regulatory bodies across the globe [Internet]. Freyr Solutions; [cited 2026 Sep 17]. Available from: https://www.freyrsolutions.com/blog/7-ways-ai-is-impacting-regulatory-bodies-across-the-globe Health Canada organization structure [Internet]. [cited 2026 Aug 19]. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1754-7121.1975.tb01937.x Central Drugs Standard Control Organisation. Regulatory workflow of CDSCO [Internet]. Available from: https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/SUGAM_user_manual.pdf [cited 2026 Sep 18].

Authors (6)

Ashok Kumar P

Department of Regulatory Affai...

View all publications →

Mithun Gowda HP

Department of Regulatory Affai...

View all publications →

Amisha S

Department of Regulatory Affai...

View all publications →

Mailarappa Gari Mounika

Department of Regulatory Affai...

View all publications →

Bindu G

Department of Regulatory Affai...

View all publications →

Harshitha M

Department of Regulatory Affai...

View all publications →

Download Article

PDF

Best for printing and citation

File size: 0.4 MB
Format: PDF

Summarise this paper with AI:

Article Information

AJPTR5160002

AJPTR-02-002508

11-31

2026-10-02

JATS XML

Article Impact

Views:1,080
Downloads:2,255

How to Cite

Kumar P, A., Gowda HP, M., S, A., Gari Mounika, M., G, B., & M, H. (2026). ARTIFICIAL INTELLIGANCE DRIVEN TRANSFORMATION IN REGULATORY AFFAIRS AS PER CDSCO in (India) IN COMPARISION WITH HEALTH CANADA (Canada). American Journal of PharmTech Research, 16(5), 11-31. https://ajptr.com/articles/AJPTR5160002

Article Actions

Whatsapp